Antibacterial activity of silver nanoparticles (AgNP) confined to mesostructured silica against methicillin-resistant Staphylococcus aureus (MRSA)

Chien, Chi-Sheng; Lin, Chao-Jen; Ko, Chih-Jung; Tseng, Sung-Pin; Shih, Chi‐Jen

doi:10.1016/j.jallcom.2018.02.334

Cited by 28 publications

(15 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Special interest is oriented toward improving the stability of AgNPs, since a particular limitation of their antimicrobial-related use arises from their instability in bacteria-rich environments, and consequently, diminution or deprivation of their anti-pathogenic activity. In order to improve the stability of AgNPs in solution, many inorganic and organic [ 30 , 31 ], synthetic and natural [ 32 , 33 ], and biotic and abiotic materials were used as capping agents [ 34 ].…”

Section: Introductionmentioning

confidence: 99%

Biomedical Applications of Silver Nanoparticles: An Up-to-Date Overview

et al. 2018

View full text Add to dashboard Cite

During the past few years, silver nanoparticles (AgNPs) became one of the most investigated and explored nanotechnology-derived nanostructures, given the fact that nanosilver-based materials proved to have interesting, challenging, and promising characteristics suitable for various biomedical applications. Among modern biomedical potential of AgNPs, tremendous interest is oriented toward the therapeutically enhanced personalized healthcare practice. AgNPs proved to have genuine features and impressive potential for the development of novel antimicrobial agents, drug-delivery formulations, detection and diagnosis platforms, biomaterial and medical device coatings, tissue restoration and regeneration materials, complex healthcare condition strategies, and performance-enhanced therapeutic alternatives. Given the impressive biomedical-related potential applications of AgNPs, impressive efforts were undertaken on understanding the intricate mechanisms of their biological interactions and possible toxic effects. Within this review, we focused on the latest data regarding the biomedical use of AgNP-based nanostructures, including aspects related to their potential toxicity, unique physiochemical properties, and biofunctional behaviors, discussing herein the intrinsic anti-inflammatory, antibacterial, antiviral, and antifungal activities of silver-based nanostructures.

show abstract

Section: Introductionmentioning

confidence: 99%

Biomedical Applications of Silver Nanoparticles: An Up-to-Date Overview

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Differences in the actual MIC values could be attributed to differences in the properties of nanoparticles and the strains of bacteria used. Bacterial killing was seen in much lesser concentrations of silver nanoparticles than reported by Chien et al [26]. When one compares the results reported here to antimicrobial activity of selenium nanoparticles or chitosan/silver nanoparticles against MRSA, silver nanoparticles coated in PVP are shown to be active at lower concentrations [27,28].…”

Section: Introductionmentioning

confidence: 64%

Augmented antibacterial activity of ampicillin with silver nanoparticles against methicillin-resistant Staphylococcus aureus (MRSA)

et al. 2018

View full text Add to dashboard Cite

At present, including failed attempts, it takes about 15 years and costs totaling up to $2.6 billion to take a promising new compound from laboratory to the market. Increasing drug resistance among microbial pathogens has led to a growing interest in exploring novel methods to enhance the efficacy of existing drugs. Combination therapies involving two or more known antimicrobial methods, particularly those involving nanoparticles for combating the clinical problems associated with antibiotic resistance, have been garnering interest. In the current study, we determined whether a combination therapy involving silver nanoparticles, which are known for their antimicrobial activity, and the widely used antibiotic ampicillin can be effective against methicillin-resistant Staphylococcus aureus (MRSA). In the presence of sub-lethal dose of silver nanoparticles, ampicillin was found to be effective against MRSA. Indeed, the results show that silver nanoparticles and ampicillin act synergistically, with the effect being more pronounced when a lower concentration of ampicillin is present. When present at a higher concentration, ampicillin coats the silver nanoparticle, preventing the direct interaction of nanoparticles and bacteria. This study discusses the possible applications of combination antimicrobial therapies involving silver nanoparticles for therapeutic treatments.

show abstract

“…In this study, we proposed a new colloid system, casein-AgNPs (colloid type), based on our previous work, SSCP (powder type) [ 29 , 32 ]. Different forms of silver between casein-AgNPs, casein/arginine-AgNPs, and arginine-AgNPs are shown in Figure 1 .…”

Section: Resultsmentioning

confidence: 99%

“…The impact on the combination of casein/arginine-AgNPs and tigecycline was determined by broth microdilution assay in checkerboard testing as previously described [ 29 ]. The combination of casein/arginine-AgNPs and tigecycline diluted 2-fold in a 96-well microplate.…”

Section: Methodsmentioning

confidence: 99%

Synergistic Antibacterial Effect of Casein-AgNPs Combined with Tigecycline against Acinetobacter baumannii

et al. 2021

Self Cite

View full text Add to dashboard Cite

Acinetobacter baumannii (A. baumannii) is a common and challenging pathogen of nosocomial infections, due to its ability to survive on inanimate objects, desiccation tolerance, and resistance to disinfectants. In this study, we investigated an antibacterial strategy to combat A. baumannii via the combination of antibiotics and silver protein. This strategy used a functional platform consisting of silver nanoparticles (AgNPs) resurrected from silver-based calcium thiophosphate (SSCP) through casein and arginine. Then, the silver protein was combined with tigecycline, the first drug in glycylcycline antibiotic, to synergistically inhibit the viability of A. baumannii. The synergistic antibacterial activity was confirmed by the 96-well checkerboard method to determine their minimum inhibitory concentrations (MIC) and calculated for the combination index (CI). The MIC of the combination of silver protein and tigecycline (0.31 mg/mL, 0.16 µg/mL) was significantly lower than that of the individual MIC, and the CI was 0.59, which indicates a synergistic effect. Consequently, we integrated the detailed synergistic antibacterial properties when silver protein was combined with tigecycline. The result could make for a promising approach for the treatment of A. baumannii.

show abstract

Antibacterial activity of silver nanoparticles (AgNP) confined to mesostructured silica against methicillin-resistant Staphylococcus aureus (MRSA)

Cited by 28 publications

References 26 publications

Biomedical Applications of Silver Nanoparticles: An Up-to-Date Overview

Biomedical Applications of Silver Nanoparticles: An Up-to-Date Overview

Augmented antibacterial activity of ampicillin with silver nanoparticles against methicillin-resistant Staphylococcus aureus (MRSA)

Synergistic Antibacterial Effect of Casein-AgNPs Combined with Tigecycline against Acinetobacter baumannii

Contact Info

Product

Resources

About